Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
170 - When introucing a new drug can we put the Health Canada classification, i.e. Angiotensin II receptor blocker or angiotensin receptor blocker of the drug on the same page as clinical information.
-
It is possible for the Health Canada pharmacological classification and claims within the limitations of the Terms of Market Authorization to appear on a single page. However, to avoid according clinical significance to the pharmacological classification, the claims will need to be presented such that they are separate and distinct messages. Call the PAAB office if you have any questions.
